AstraZeneca (AZN.L): Mixed lung cancer updates across the portfolio; eVOLVE-Lung02 discontinuation improves 2027 catalyst set up 17 August 2026 | 8:52AM BST Equity Research This morning, AZN announced: 1) positive topline results from the Phase 3 SAFFRON trial, where Tagrisso plus Orpathys (MET inhibitor) showed positive PFS and OS results in 2L EGFR+ MET+ NSCLC; 2) discontinuation of the Phase 3 eVOLVE-Lung02 trial testing volrustomig (PD-1xCTLA-4) + chemo vs. Keytruda + chemo in PD-L1 low (<50%) NSCLC at ...

C A Z E N O V E Europe Equity Research 17 August 2026 AstraZeneca Clinically meaningful SAFFRON data for Tagrisso and Orpathys, and Enhertu DL04 success partially offset by discontinuation of eVOLVE-Lung02 for volrustomig This morning, Astra announced the results from three read-outs; (i) the SAFFRON trial for Tagrisso + Orpathys in 2L+ EGFRm NSCLC, which showed a statistically significant and clinically meaningful benefit on PFS and OS; (ii) the Destiny- Lung04 results for Enhertu, which showed a statistic ...